TI
IBRX icon

Tidal Investments’s ImmunityBio IBRX Stock Holding History

Tidal Investments’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-64,255
Closed -$406K – 1898
2024
Q2 		$406K Sell
64,255
-28,584
-31% -$188K 0.01% 1404
2024
Q1 		$499K Buy
+92,839
New +$420K 0.01% 1201
2022
Q2 		– Sell
-11,219
Closed -$63K – 1139
2022
Q1 		$63K Buy
+11,219
New +$68.8K ﹤0.01% 1082

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tidal Investments's IBRX Position: Q3 2024 in Review

Tidal Investments sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 64,255 shares — an estimated $406K sold.

Tidal Investments first reported a position in IBRX in Q1 2022 and held it in 3 quarters. The position peaked at $499K in Q1 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Tidal Investments reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • Tidal Investments sold 64,255 ImmunityBio shares in Q3 2024, an estimated $406K.
  • Tidal Investments first reported a position in ImmunityBio in Q1 2022 and held it in 3 quarters.
  • Tidal Investments's ImmunityBio position peaked at $499K in Q1 2024.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Tidal Investments's 13F filing for Q3 2024, filed 14 Nov 2024.